Critical Contrast: BioCardia (BCDA) versus Its Peers

BioCardia (NASDAQ:BCDA) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare BioCardia to similar businesses based on the strength of its profitability, risk, valuation, earnings, institutional ownership, dividends and analyst recommendations.

Earnings and Valuation

This table compares BioCardia and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioCardia	$60,000.00	-$8.23 million	-1.35
BioCardia Competitors	$689.45 million	$10.37 million	-10.05

BioCardia’s peers have higher revenue and earnings than BioCardia. BioCardia is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioCardia and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1	1	1	0	2.00
BioCardia Competitors	9773	15031	45238	1571	2.54

BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 2,803.60%. As a group, “Biotechnology” companies have a potential upside of 95.32%. Given BioCardia’s higher probable upside, research analysts clearly believe BioCardia is more favorable than its peers.

Profitability

This table compares BioCardia and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
BioCardia Competitors	-9,054.31%	-198.21%	-30.53%

Institutional and Insider Ownership

20.6% of BioCardia shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

BioCardia has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, BioCardia’s peers have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.

Summary

BioCardia peers beat BioCardia on 9 of the 13 factors compared.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.